NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Forecast, Price & News $3.72 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.66▼$3.9050-Day Range$0.21▼$8.6952-Week Range$3.36▼$140.99Volume20,826 shsAverage Volume22,932 shsMarket Capitalization$3.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability About Agile Therapeutics (NASDAQ:AGRX) StockAgile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.Read More Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGRX Stock News HeadlinesMay 26, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Announces Closing of $7.5 Million Public OfferingMay 25, 2023 | finance.yahoo.comAgile Therapeutics Announces Closing of $7.5 Million Public OfferingJune 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 23, 2023 | msn.comAgile Therapeutics prices $7.5M offeringMay 23, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Upgraded to "Hold" by StockNews.comMay 22, 2023 | finance.yahoo.comAgile Therapeutics Announces Pricing of $7.5 Million Public OfferingMay 13, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Hold Rating for Agile Therapeutics (AGRX)May 12, 2023 | finance.yahoo.comQ1 2023 Agile Therapeutics Inc Earnings CallJune 2, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.May 12, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Upgraded to Hold by StockNews.comMay 12, 2023 | americanbankingnews.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Sees Significant Increase in Short InterestMay 11, 2023 | msn.comAgile Therapeutics: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comAgile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comAgile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comAgile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023May 1, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Cut to Sell at StockNews.comApril 30, 2023 | americanbankingnews.comStockNews.com Lowers Agile Therapeutics (NASDAQ:AGRX) to SellApril 28, 2023 | finance.yahoo.comAgile Therapeutics Announces Preliminary Expectations for First Quarter 2023April 26, 2023 | finance.yahoo.comAgile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementApril 23, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Stock Price Crosses Above Fifty Day Moving Average of $1.52April 16, 2023 | americanbankingnews.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest UpdateApril 14, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.comApril 11, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Announces 1-For-50 Reverse Stock SplitApril 10, 2023 | finance.yahoo.comAgile Therapeutics Announces 1-For-50 Reverse Stock SplitApril 5, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.comMarch 28, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.comMarch 27, 2023 | finance.yahoo.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2022 Earnings Call TranscriptSee More Headlines AGRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGRX Company Calendar Last Earnings3/22/2023Today6/02/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees28Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($172.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,410,000.00 Net Margins-318.50% Pretax Margin-157.82% Return on Equity-2,658.43% Return on Assets-177.29% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.47 Sales & Book Value Annual Sales$10.88 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value($9.54) per share Price / Book-0.39Miscellaneous Outstanding Shares990,000Free Float984,000Market Cap$3.69 million OptionableOptionable Beta1.15 Key ExecutivesAl AltomariChairman & Chief Executive OfficerJason ButchChief Accounting & Financial Officer, VPPaul KornerChief Medical OfficerRobert G. ConwayChief Supply Chain Officer & Senior Vice PresidentGeoffrey P. GilmoreChief Administrative OfficerKey CompetitorsTransCode TherapeuticsNASDAQ:RNAZHistogenNASDAQ:HSTODermata TherapeuticsNASDAQ:DRMAFirst Wave BioPharmaNASDAQ:FWBISalarius PharmaceuticalsNASDAQ:SLRXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 23,796 shares on 5/1/2023Ownership: 12.785%Alfred AltomariBought 50,000 shares on 8/26/2022Total: $22,500.00 ($0.45/share)View All Insider TransactionsView All Institutional Transactions AGRX Stock - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. How have AGRX shares performed in 2023? Agile Therapeutics' stock was trading at $0.2270 on January 1st, 2023. Since then, AGRX stock has increased by 1,543.2% and is now trading at $3.73. View the best growth stocks for 2023 here. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 67,900 shares, an increase of 46.0% from the April 30th total of 46,500 shares. Based on an average trading volume of 25,800 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.9% of the shares of the company are short sold. View Agile Therapeutics' Short Interest. When is Agile Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our AGRX earnings forecast. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings results on Wednesday, March, 22nd. The specialty pharmaceutical company reported ($9.00) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $1.50. The specialty pharmaceutical company had revenue of $4 million for the quarter, compared to analysts' expectations of $3.17 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 318.50%. When did Agile Therapeutics' stock split? Agile Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Agile Therapeutics issued on next quarter's earnings? Agile Therapeutics issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Virtu Financial LLC (12.78%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $3.73. How much money does Agile Therapeutics make? Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.69 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($172.91) on an earnings per share basis. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com. This page (NASDAQ:AGRX) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.